Press releases
- Neurocrine Biosciences Launches INGREZZA® SPRINKLE (valbenazine) Capsules to Ease Administration for Patients Experiencing Dysphagia or Difficulty Swallowing
- Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2024 Financial Results
- Neurocrine Biosciences Announces U.S. FDA Accepts New Drug Applications and Grants Priority Review for Crinecerfont for Pediatric and Adult Patients with CAH
- Neurocrine Biosciences Presented CAHtalyst™ Phase 3 Pediatric and Adult Studies, CAHtalog™ Registry and Disease- and Glucocorticoid-Related Comorbidities Data in CAH at ENDO 2024
- Neurocrine Biosciences Announces Publication of Primary CAHtalyst™ Pediatric Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine
- Neurocrine Biosciences Announces Publication of Primary CAHtalyst™ Adult Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine
- Neurocrine Biosciences to Participate at Investor Conferences in June
- Neurocrine Biosciences Announces CEO Succession Plan
- Neurocrine Biosciences to Present New Phase 3 CAHtalyst™ Data in Adult and Pediatric Patients with CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ENDO 2024
- Neurocrine Biosciences Announces Publication of Phase 3 KINECT®-4 Post Hoc Analysis Demonstrating Clinically Meaningful and Sustained Improvement in Tardive Dyskinesia With Long-Term Use of INGREZZA® (valbenazine) Capsules
More ▼
Key statistics
As of last trade Neurocrine Biosciences Inc (NB3:BRN) traded at 134.83, 0.00% below its 52-week high of 134.83, set on May 08, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 134.83 |
---|---|
High | 134.83 |
Low | 134.83 |
Bid | 128.02 |
Offer | 128.51 |
Previous close | 134.83 |
Average volume | -- |
---|---|
Shares outstanding | 100.64m |
Free float | 98.82m |
P/E (TTM) | 39.75 |
Market cap | 14.56bn USD |
EPS (TTM) | 3.64 USD |
Data delayed at least 15 minutes, as of May 08 2024.
More ▼